AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29413434
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200 mg, twice daily
Trial: 22583627
Drug: Infrapatellar fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrapatellar fat pad-derived mesenchymal stem cell therapy combined with arthroscopic debridement and PRP injection
Trial: 22583627
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (arthroscopic debridement and PRP injection without stem cells)
Trial: 19915976
Drug: Hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal treatment for metastatic disease: yes
Trial: 18555828
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT+)
Trial: 18555828
Drug: No Hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No Hormone Replacement Therapy (HRT-)
Trial: 16866128
Drug: Control groups
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control groups receiving appropriate treatment
Trial: 12627926
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 2 g in 50 ml of 0.9% sodium chloride
Trial: 10528097
Drug: Two consecutive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two consecutive doses of 50 microg salbutamol inhaled via Turbuhaler
Trial: 10528097
Drug: Two divided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two divided doses of 50 microg salbutamol inhaled via Turbuhaler with 1.5 min between doses
Trial: 10528097
Drug: Therapeutic doses
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic doses of salbutamol via Turbuhaler
Trial: 1884725
Drug: Nifedipine-ER tablets
RxNorm normalized name: nifedipine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine-ER tablets (once daily)
Trial: 1884725
Drug: Nifedipine capsules
RxNorm normalized name: Nifedipine Capsules
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine capsules (t.d.s.)
Trial: 1884725
Drug: Nifedipine-ER tablets
RxNorm normalized name: nifedipine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine-ER tablets
Trial: 1884725
Drug: Nifedipine capsules
RxNorm normalized name: Nifedipine Capsules
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine capsules
Trial: 6846300
Drug: Antacid tablets
RxNorm normalized name: Calcium Carbonate 500 MG Oral Tablet, Chewable [GOOD SENSE ANTACID TABLETS]
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid tablets (14 mEq neutralizing capacity per tablet)
Trial: 28846633
Drug: Reconstituted freeze-dried
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted freeze-dried strawberry beverage (50 g/day)
Trial: 26244985
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab (176 patients)
Trial: 26244985
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (194 patients)
Trial: 26244985
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab (high LDH subgroup)
Trial: 26244985
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (high LDH subgroup)
Trial: 20337570
Drug: Indirect language
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect language therapy delivered by school staff using a consultancy model
Trial: 20337570
Drug: Manualized language
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualized language therapy delivered by speech and language therapists or assistants
Trial: 19108423
Drug: Acupotomy-injection combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupotomy-injection combined with Feng's spinal manipulation (FSM)
Trial: 16580444
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate administered to increase plasma levels 1(1/2) to 2 times normal during cardiopulmonary bypass, n = 174
Trial: 10902991
Drug: Control (M)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (M) = 12 mg iron + 209 kJ
Trial: 8436004
Drug: Medical termination
RxNorm normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medical termination of pregnancy with mifepristone (200 mg) and gemeprost (1 mg)
Trial: 8436004
Drug: Medical termination
RxNorm normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medical termination of pregnancy with mifepristone (400 mg) and gemeprost (1 mg)
Trial: 8436004
Drug: Medical termination
RxNorm normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medical termination of pregnancy with mifepristone (600 mg) and gemeprost (1 mg)
Trial: 2992530
Drug: suloctidil (Locton)
RxNorm normalized name: suloctidil
DrugBank: Suloctidil (DB13340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suloctidil (Locton) at a daily dose of 200 mg X 3 for 180 days
Trial: 22891564
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy (average 18.47 +/- 8.81 mCi)
Trial: 22891564
Drug: Thiamazole treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamazole treatment before radioiodine therapy
Trial: 18550953
Drug: Concurrent strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent strength and endurance (CSE) training
Trial: 7584685
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms once or twice daily
Trial: 7584685
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aqueous nasal spray (BPD) 200 micrograms twice daily
Trial: 17520566
Drug: Regional heparinization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional heparinization (heparin 1500 IU/h pre-filter, protamine 15 mg/h post-filter)
Trial: 17520566
Drug: Regional citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional citrate anticoagulation (citrate-based replacement fluid 14 mmol/L pre-dilution)
Trial: 11114960
Drug: Cholestyramine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (6 g three times a day)
Trial: 19332518
Drug: Parotid gland-sparing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parotid gland-sparing intensity-modulated radiation therapy (IMRT)
Trial: 17897465
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone for 12 months
Trial: 9793844
Drug: Long-term therapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term therapy with captopril (75 mg/day, n = 13)
Trial: 9793844
Drug: Long-term therapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term therapy with nifedipine (40 mg/day, n = 12)
Trial: 7894825
Drug: Artemether administered
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether administered intramuscularly twice daily (1.6 or 3.2 mg/kg/day)
Trial: 2558817
Drug: Soluble insulin
RxNorm normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soluble insulin 0.15U/kg
Trial: 2558817
Drug: Soluble insulin
RxNorm normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soluble insulin 0.15U/kg followed by oCRF41 100 micrograms
Trial: 344108
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum (C.p.) 5 mg/sc/m2 on day 1 in addition to CAO/CMF
Trial: 30598342
Drug: Solriamfetol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol (300 mg) in fasted condition
Trial: 30598342
Drug: Solriamfetol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol (300 mg) in fed condition
Trial: 17459480
Drug: LTFC (Latanoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTFC (Latanoprost and Timolol Fixed Combination)
Trial: 11704081
Drug: Dim light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim light therapy (DLT)
Trial: 8199567
Drug: High-dose cyclosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclosporin (CsA)
Trial: 8199567
Drug: Low-dose cyclosporin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporin (CsA)
Trial: 3587902
Drug: Concurrent multiagent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent multiagent chemotherapy and orbital radiation therapy after initial partial tumor resection
Trial: 29606517
Drug: F4/AS01B HIV-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F4/AS01B HIV-1 vaccine candidate
Trial: 20802351
Drug: AZD6244 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6244 (100 mg oral free-base suspension twice daily)
Trial: 20802351
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2 intravenous once every 3 weeks)
Trial: 19054833
Drug: Nicotinell TTS
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinell TTS 20 patch (single dose)
Trial: 19054833
Drug: Nicotinell TTS
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinell TTS 20 patch (multiple doses over 4 days)
Trial: 14646626
Drug: Cisplatin at
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin at a dose of 150 mg/m2 and WR‐2721 at a dose of 910 mg/m2
Trial: 14646626
Drug: Cisplatin alone
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin alone at a dose of 120 mg/m2
Trial: 10671837
Drug: Background infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background infusion of 5 ml x h‐1 (Group B)
Trial: 10671837
Drug: No background
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No background infusion (Group N)
Trial: 8826489
Drug: Topical aspirin/diethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aspirin/diethyl ether (ADE) mixture
Trial: 1594261
Drug: Indomethacin and
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin and diclofenac drug/ether mixtures
Trial: 6705752
Drug: Flunarizine (add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (add-on therapy)
Trial: 14504005
Drug: Alprostadil 500
RxNorm normalized name: ALPROSTADIL 500MCG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprostadil 500 g cream
Trial: 14504005
Drug: Alprostadil 1000
RxNorm normalized name: ALPROSTADIL 1000MCG SUPP,URETHRAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprostadil 1000 g cream
Trial: 14504005
Drug: Alprostadil 1500
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil 1500 g cream
Trial: 10348802
Drug: Single-dose disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose disulfiram
Trial: 8547045
Drug: 8-methoxypsoralen (8-MOP)
RxNorm normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-methoxypsoralen (8-MOP) calculated according to body weight (0.6 mg/kg)
Trial: 8547045
Drug: 8-methoxypsoralen (8-MOP)
RxNorm normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-methoxypsoralen (8-MOP) calculated according to body surface area (25 mg/m2)
Trial: 8547045
Drug: 8-methoxypsoralen (8-MOP)
RxNorm normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-methoxypsoralen (8-MOP) doses of 40 or 50 mg based on body surface area
Trial: 7017074
Drug: 10% ointment
RxNorm normalized name: Tiger Balm Red Extra Strength 11%-10% Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% ointment from 95% ethanol extract of Lupinus termis seeds
Trial: 7017074
Drug: 0.02% flumethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% flumethasone pivalate ointment
Trial: 30577819
Drug: Immediate Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate Intervention (n=30) received a Fitbit® Flex™ and four bi-weekly activity counselling sessions
Trial: 22500821
Drug: Pegnivacogin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegnivacogin 0.5 mg kg(‐1)
Trial: 22500821
Drug: Pegnivacogin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegnivacogin 1.0 mg kg(‐1)
Trial: 22500821
Drug: Pegnivacogin 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegnivacogin 3.0 mg kg(‐1)
Trial: 22500821
Drug: Pegnivacogin 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegnivacogin 2.0 mg kg(‐1)
Trial: 22500821
Drug: Anivamersen (single-dose)
RxNorm normalized name: Anivamersen
DrugBank: Anivamersen (DB16089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anivamersen (single-dose)
Trial: 20399240
Drug: DTaP/Hib combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP/Hib combination vaccine (3 doses at 3, 4, and 5 months)
Trial: 20399240
Drug: Separate licensed
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate licensed DTaP vaccine and Hib conjugate vaccine (3 doses at 3, 4, and 5 months)
Trial: 8806255
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with antiretroviral drugs
Trial: 1988512
Drug: Bivalent attenuated
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent attenuated (CR) vaccine
Trial: 1988512
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated (TI) vaccine
Trial: 24555576
Drug: PDE-5 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDE-5 inhibitors in adequately blinded trials
Trial: 24555576
Drug: PDE-5 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDE-5 inhibitors in inadequately blinded trials
Trial: 16216094
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg dose of inhaler (powder inhaler)
Trial: 16216094
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg dose of inhaler (remaining powder)
Trial: 2150105
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (first- or second-generation cephalosporins)
Trial: 6941373
Drug: Combined injection
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined injection of 3.0 mg/kg cimetidine and 0.3 mg/kg pirenzepine
Trial: 6941373
Drug: Combined injection
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined injection of 1.5 mg/kg cimetidine, 0.075 and 0.15 mg/kg pirenzepine
Trial: 31286732
Drug: Umbilical needling
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical needling therapy of I-Ching; treatment at 1 PM to 3 PM, once a day for 20 days.
Trial: 31286732
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment of western medicine combined with TCM decoction; control group.
Trial: 25769541
Drug: Continuous lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous lenalidomide and low-dose dexamethasone
Trial: 25769541
Drug: Fixed cycles
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed cycles of lenalidomide and low-dose dexamethasone for 18 months
Trial: 21500011
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity (three times weekly)
Trial: 21500011
Drug: Mental activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental activity (three times weekly)
Trial: 14984440
Drug: Betamethasone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (60 mg)
Trial: 14984440
Drug: Methylprednisolone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (400 mg)
Trial: 9342783
Drug: Melatonin (MLT;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (MLT; 3 mg)
Trial: 9342783
Drug: Melatonin (MLT;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (MLT; 9 mg)
Trial: 9342783
Drug: Melatonin (MLT;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (MLT; 3 mg or 9 mg)
Trial: 4041370
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A in combination with antilymphocyte serum
Trial: 29561377
Drug: 4.5-mm-wide titanium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5-mm-wide titanium implant
Trial: 29561377
Drug: 3.75-mm-wide titanium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75-mm-wide titanium implant
Trial: 21613553
Drug: Yogurt consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt consumption >100 g/d
Trial: 19549290
Drug: Masitinib 3
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Masitinib 3 mg/kg per day
Trial: 19549290
Drug: Masitinib 6
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Masitinib 6 mg/kg per day
Trial: 9038130
Drug: Gd‐EOB‐DTPA (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gd‐EOB‐DTPA (12.5, 25, or 50 micromol/kg body weight) administered as an IV bolus
Trial: 7912123
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin 7.5 g every 4 weeks for 1 year
Trial: 7912123
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin 40 g every 4 weeks for 1 year
Trial: 7912123
Drug: Standard HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard HIV treatment (control group)
Trial: 28554910
Drug: Twice-daily supportive
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily supportive SMS text messages for 6 months plus treatment as usual
Trial: 22924260
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) with energy dose of 0.1 J per point
Trial: 22924260
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) with energy dose of 1 J per point
Trial: 22924260
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) with energy dose of 4 J per point
Trial: 12878619
Drug: Tramadol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (1 mg kg(‐1))
Trial: 12878619
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg kg(‐1))
Trial: 12878619
Drug: Saline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (2 ml)
Trial: 10381027
Drug: Two methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two methods (self-completion and interviewer administration)
Trial: 10381027
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in method of administration